« Previous
Next »
Titles
- Alternative procedures for blood and blood components during the COVID-19 public health emergency1
- Nucleic acid testing (NAT) for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV): testing, product disposition, and donor deferral and reentry1
- Recommendations for evaluating donor eligibility using individual risk-based questions to reduce the risk of human immunodeficiency virus transmission by blood and blood products: guidance for industry1
- Recommendations to reduce the possible risk of transmission of Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease by blood and blood components1
- Revised recommendations for reducing the risk of Zika virus transmission by blood and blood components1
- Revised recommendations for reducing the risk of human immunodeficiency virus transmission by blood and blood products1
- Revised recommendations to reduce the risk of transfusion-transmitted malaria1